Translation of experimental cardioprotective capability of P2Y
Aged
Animals
Blood Platelets
/ drug effects
Clopidogrel
/ therapeutic use
Disease Models, Animal
Female
Humans
Male
Middle Aged
Myocardial Reperfusion Injury
/ blood
Percutaneous Coronary Intervention
/ adverse effects
Platelet Aggregation
/ drug effects
Platelet Aggregation Inhibitors
/ adverse effects
Prasugrel Hydrochloride
/ therapeutic use
Purinergic P2Y Receptor Antagonists
/ adverse effects
Randomized Controlled Trials as Topic
Rats
Receptors, Purinergic P2Y12
/ drug effects
Retrospective Studies
ST Elevation Myocardial Infarction
/ physiopathology
Ticagrelor
/ therapeutic use
Translational Research, Biomedical
Treatment Outcome
Cardioprotection
Ischemic conditioning
Myocardial infarction
P2Y12 inhibitor
Journal
Basic research in cardiology
ISSN: 1435-1803
Titre abrégé: Basic Res Cardiol
Pays: Germany
ID NLM: 0360342
Informations de publication
Date de publication:
26 05 2021
26 05 2021
Historique:
received:
21
12
2020
accepted:
13
04
2021
entrez:
26
5
2021
pubmed:
27
5
2021
medline:
15
12
2021
Statut:
epublish
Résumé
We studied the translational cardioprotective potential of P2Y
Identifiants
pubmed: 34037861
doi: 10.1007/s00395-021-00870-y
pii: 10.1007/s00395-021-00870-y
doi:
Substances chimiques
P2ry12 protein, rat
0
Platelet Aggregation Inhibitors
0
Purinergic P2Y Receptor Antagonists
0
Receptors, Purinergic P2Y12
0
Clopidogrel
A74586SNO7
Prasugrel Hydrochloride
G89JQ59I13
Ticagrelor
GLH0314RVC
Types de publication
Comparative Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
36Subventions
Organisme : Danish Innovation Foundation
ID : 11-108354
Organisme : British Heart Foundation
ID : FS/10/039/28270
Pays : United Kingdom
Organisme : National Medical Research Council
ID : NMRC/CGAug16C006
Organisme : European Cooperation in Science and Technology
ID : CA16225
Organisme : National Medical Research Council
ID : NMRC/CSA-SI/0011/2017
Organisme : Danish Innovation Foundation
ID : 11-115818
Organisme : Medical Research Council
ID : MC_G1002673
Pays : United Kingdom
Organisme : British Heart Foundation
ID : CS/14/3/31002
Pays : United Kingdom
Organisme : British Heart Foundation Clinical Study Grant
ID : CS/14/3/31002
Organisme : Novo Nordisk Fonden (DK)
ID : NNF13OC0007447
Commentaires et corrections
Type : CommentIn
Références
Alexopoulos D, Moulias A, Koutsogiannis N, Xanthopoulou I, Kakkavas A, Mavronasiou E, Davlouros P, Hahalis G (2013) Differential effect of ticagrelor versus prasugrel on coronary blood flow velocity in patients with non-ST-elevation acute coronary syndrome undergoing percutaneous coronary intervention: an exploratory study. Circ Cardiovasc Interv 6:277–283. https://doi.org/10.1161/CIRCINTERVENTIONS.113.000293
doi: 10.1161/CIRCINTERVENTIONS.113.000293
pubmed: 23735473
Alexopoulos D, Xanthopoulou I, Gkizas V, Kassimis G, Theodoropoulos KC, Makris G, Koutsogiannis N, Damelou A, Tsigkas G, Davlouros P, Hahalis G (2012) Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction. Circ Cardiovasc Interv 5:797–804. https://doi.org/10.1161/CIRCINTERVENTIONS.112.972323
doi: 10.1161/CIRCINTERVENTIONS.112.972323
pubmed: 23169985
Audia JP, Yang XM, Crockett ES, Housley N, Haq EU, O’Donnell K, Cohen MV, Downey JM, Alvarez DF (2018) Caspase-1 inhibition by VX-765 administered at reperfusion in P2Y12 receptor antagonist-treated rats provides long-term reduction in myocardial infarct size and preservation of ventricular function. Basic Res Cardiol 113:32. https://doi.org/10.1007/s00395-018-0692-z
doi: 10.1007/s00395-018-0692-z
pubmed: 29992382
pmcid: 6396295
Aytekin A, Ndrepepa G, Neumann FJ, Menichelli M, Mayer K, Wohrle J, Bernlochner I, Lahu S, Richardt G, Witzenbichler B, Sibbing D, Cassese S, Angiolillo DJ, Valina C, Kufner S, Liebetrau C, Hamm CW, Xhepa E, Hapfelmeier A, Sager HB, Wustrow I, Joner M, Trenk D, Fusaro M, Laugwitz KL, Schunkert H, Schupke S, Kastrati A (2020) Ticagrelor or prasugrel in patients with ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention. Circulation 142:2329–2337. https://doi.org/10.1161/CIRCULATIONAHA.120.050244
doi: 10.1161/CIRCULATIONAHA.120.050244
pubmed: 33115278
Baker JE, Konorev EA, Gross GJ, Chilian WM, Jacob HJ (2000) Resistance to myocardial ischemia in five rat strains: is there a genetic component of cardioprotection? Am J Physiol Heart Circ Physiol 278:H1395-1400. https://doi.org/10.1152/ajpheart.2000.278.4.H1395
doi: 10.1152/ajpheart.2000.278.4.H1395
pubmed: 10749737
Barletta KE, Ley K, Mehrad B (2012) Regulation of neutrophil function by adenosine. Arterioscler Thromb Vasc Biol 32:856–864. https://doi.org/10.1161/ATVBAHA.111.226845
doi: 10.1161/ATVBAHA.111.226845
pubmed: 22423037
pmcid: 3353547
Barrabes JA, Inserte J, Mirabet M, Quiroga A, Hernando V, Figueras J, Garcia-Dorado D (2010) Antagonism of P2Y12 or GPIIb/IIIa receptors reduces platelet-mediated myocardial injury after ischaemia and reperfusion in isolated rat hearts. Thromb Haemost 104:128–135. https://doi.org/10.1160/TH09-07-0440
doi: 10.1160/TH09-07-0440
pubmed: 20431845
Bergmeijer TO, Godschalk TC, Janssen PWA, Berge KVD, Breet NJ, Kelder JC, Hackeng CM, Ten Berg JM (2017) How long does it take for clopidogrel and ticagrelor to inhibit platelets in patients undergoing primary percutaneous coronary intervention? A detailed pharmacodynamic analysis: time course of platelet reactivity in STEMI (TOPS). Semin Thromb Hemost 43:439–446. https://doi.org/10.1055/s-0037-1599156
doi: 10.1055/s-0037-1599156
pubmed: 28561235
Birnbaum Y, Birnbaum GD, Birnbaum I, Nylander S, Ye Y (2016) Ticagrelor and rosuvastatin have additive cardioprotective effects via adenosine. Cardiovasc Drugs Ther 30:539–550. https://doi.org/10.1007/s10557-016-6701-2
doi: 10.1007/s10557-016-6701-2
pubmed: 27830382
Bonello L, Laine M, Camoin-Jau L, Noirot F, Guieu R, Dignat-George F, Paganelli F, Frere C (2015) Onset of optimal P2Y12-ADP receptor blockade after ticagrelor and prasugrel intake in Non-ST elevation acute coronary syndrome. Thromb Haemost 114:702–707. https://doi.org/10.1160/TH15-02-0149
doi: 10.1160/TH15-02-0149
pubmed: 26311415
Botker HE (2020) The future of cardioprotection-pointing toward patients at elevated risk as the target populations. J Cardiovasc Pharmacol Ther 25:487–493. https://doi.org/10.1177/1074248420937871
doi: 10.1177/1074248420937871
pubmed: 32597205
Botker HE (2021) Searching myocardial rescue through intermittent upper arm occlusion and lizard saliva. Basic Res Cardiol 116:5. https://doi.org/10.1007/s00395-021-00843-1
doi: 10.1007/s00395-021-00843-1
pubmed: 33495904
Botker HE, Hausenloy D, Andreadou I, Antonucci S, Boengler K, Davidson SM, Deshwal S, Devaux Y, Di Lisa F, Di Sante M, Efentakis P, Femmino S, Garcia-Dorado D, Giricz Z, Ibanez B, Iliodromitis E, Kaludercic N, Kleinbongard P, Neuhauser M, Ovize M, Pagliaro P, Rahbek-Schmidt M, Ruiz-Meana M, Schluter KD, Schulz R, Skyschally A, Wilder C, Yellon DM, Ferdinandy P, Heusch G (2018) Practical guidelines for rigor and reproducibility in preclinical and clinical studies on cardioprotection. Basic Res Cardiol 113:39. https://doi.org/10.1007/s00395-018-0696-8
doi: 10.1007/s00395-018-0696-8
pubmed: 30120595
pmcid: 6105267
Botker HE, Kharbanda R, Schmidt MR, Bottcher M, Kaltoft AK, Terkelsen CJ, Munk K, Andersen NH, Hansen TM, Trautner S, Lassen JF, Christiansen EH, Krusell LR, Kristensen SD, Thuesen L, Nielsen SS, Rehling M, Sorensen HT, Redington AN, Nielsen TT (2010) Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial. Lancet 375:727–734. https://doi.org/10.1016/S0140-6736(09)62001-8
doi: 10.1016/S0140-6736(09)62001-8
pubmed: 20189026
Brookhart MA, Schneeweiss S, Rothman KJ, Glynn RJ, Avorn J, Sturmer T (2006) Variable selection for propensity score models. Am J Epidemiol 163:1149–1156. https://doi.org/10.1093/aje/kwj149
doi: 10.1093/aje/kwj149
pubmed: 16624967
Brookhart MA, Wyss R, Layton JB, Sturmer T (2013) Propensity score methods for confounding control in nonexperimental research. Circ Cardiovasc Qual Outcomes 6:604–611. https://doi.org/10.1161/CIRCOUTCOMES.113.000359
doi: 10.1161/CIRCOUTCOMES.113.000359
pubmed: 24021692
pmcid: 4032088
Cohen MV, Downey JM (2020) What are optimal P2Y12 inhibitor and schedule of administration in patients with acute coronary syndrome? J Cardiovasc Pharmacol Ther 25:121–130. https://doi.org/10.1177/1074248419882923
doi: 10.1177/1074248419882923
pubmed: 31645108
Cohen MV, Yang XM, White J, Yellon DM, Bell RM, Downey JM (2016) Cangrelor-mediated cardioprotection requires platelets and sphingosine phosphorylation. Cardiovasc Drugs Ther 30:229–232. https://doi.org/10.1007/s10557-015-6633-2
doi: 10.1007/s10557-015-6633-2
pubmed: 26780906
Committee CS (1996) A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 348:1329–1339. https://doi.org/10.1016/s0140-6736(96)09457-3
doi: 10.1016/s0140-6736(96)09457-3
Crump RK, Hotz VJ, Imbens GW, Mitnik OA (2009) Dealing with limited overlap in estimation of average treatment effects. Biometrika 96:187–199. https://doi.org/10.1093/biomet/asn055
doi: 10.1093/biomet/asn055
Csoka B, Nemeth ZH, Rosenberger P, Eltzschig HK, Spolarics Z, Pacher P, Selmeczy Z, Koscso B, Himer L, Vizi ES, Blackburn MR, Deitch EA, Hasko G (2010) A2B adenosine receptors protect against sepsis-induced mortality by dampening excessive inflammation. J Immunol 185:542–550. https://doi.org/10.4049/jimmunol.0901295
doi: 10.4049/jimmunol.0901295
pubmed: 20505145
Davidson SM, Andreadou I, Barile L, Birnbaum Y, Cabrera-Fuentes HA, Cohen MV, Downey JM, Girao H, Pagliaro P, Penna C, Pernow J, Preissner KT, Ferdinandy P (2019) Circulating blood cells and extracellular vesicles in acute cardioprotection. Cardiovasc Res 115:1156–1166. https://doi.org/10.1093/cvr/cvy314
doi: 10.1093/cvr/cvy314
pubmed: 30590395
Davidson SM, Ferdinandy P, Andreadou I, Botker HE, Heusch G, Ibanez B, Ovize M, Schulz R, Yellon DM, Hausenloy DJ, Garcia-Dorado D, Action CC (2019) Multitarget strategies to reduce myocardial ischemia/reperfusion injury: JACC review topic of the week. J Am Coll Cardiol 73:89–99. https://doi.org/10.1016/j.jacc.2018.09.086
doi: 10.1016/j.jacc.2018.09.086
pubmed: 30621955
De Backer O, Ratcovich H, Biasco L, Pedersen F, Helqvist S, Saunamaki K, Tilsted HH, Clemmensen P, Olivecrona G, Kelbaek H, Jorgensen E, Engstrom T, Holmvang L (2015) Prehospital administration of P2Y12 inhibitors and early coronary reperfusion in primary PCI: an observational comparative study. Thromb Haemost 114:623–631. https://doi.org/10.1160/TH15-01-0026
doi: 10.1160/TH15-01-0026
pubmed: 25994355
Dost T (2020) Cardioprotective properties of the platelet P2Y12 receptor inhibitor prasugrel on cardiac ischemia/reperfusion injury. Pharmacol Rep 72:672–679. https://doi.org/10.1007/s43440-019-00046-5
doi: 10.1007/s43440-019-00046-5
pubmed: 32048257
Franchi F, Rollini F, Rivas A, Wali M, Briceno M, Agarwal M, Shaikh Z, Nawaz A, Silva G, Been L, Smairat R, Kaufman M, Pineda AM, Suryadevara S, Soffer D, Zenni MM, Bass TA, Angiolillo DJ (2019) Platelet inhibition with cangrelor and crushed ticagrelor in patients with ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention. Circulation 139:1661–1670. https://doi.org/10.1161/CIRCULATIONAHA.118.038317
doi: 10.1161/CIRCULATIONAHA.118.038317
pubmed: 30630341
Hausenloy DJ, Candilio L, Evans R, Ariti C, Jenkins DP, Kolvekar S, Knight R, Kunst G, Laing C, Nicholas J, Pepper J, Robertson S, Xenou M, Clayton T, Yellon DM, Investigators ET (2015) Remote ischemic preconditioning and outcomes of cardiac surgery. N Engl J Med 373:1408–1417. https://doi.org/10.1056/NEJMoa1413534
doi: 10.1056/NEJMoa1413534
pubmed: 26436207
Hausenloy DJ, Chilian W, Crea F, Davidson SM, Ferdinandy P, Garcia-Dorado D, van Royen N, Schulz R, Heusch G (2019) The coronary circulation in acute myocardial ischaemia/reperfusion injury: a target for cardioprotection. Cardiovasc Res 115:1143–1155. https://doi.org/10.1093/cvr/cvy286
doi: 10.1093/cvr/cvy286
pubmed: 30428011
Hausenloy DJ, Kharbanda RK, Moller UK, Ramlall M, Aaroe J, Butler R, Bulluck H, Clayton T, Dana A, Dodd M, Engstrom T, Evans R, Lassen JF, Christensen EF, Garcia-Ruiz JM, Gorog DA, Hjort J, Houghton RF, Ibanez B, Knight R, Lippert FK, Lonborg JT, Maeng M, Milasinovic D, More R, Nicholas JM, Jensen LO, Perkins A, Radovanovic N, Rakhit RD, Ravkilde J, Ryding AD, Schmidt MR, Riddervold IS, Sorensen HT, Stankovic G, Varma M, Webb I, Terkelsen CJ, Greenwood JP, Yellon DM, Botker HE, Investigators C-E-P (2019) Effect of remote ischaemic conditioning on clinical outcomes in patients with acute myocardial infarction (CONDI-2/ERIC-PPCI): a single-blind randomised controlled trial. Lancet 394:1415–1424. https://doi.org/10.1016/S0140-6736(19)32039-2
doi: 10.1016/S0140-6736(19)32039-2
pubmed: 31500849
pmcid: 6891239
Hernán MA, Robins JM (2020) Causal inference: what if. Chapman & Hall/CRC, Boca Raton (forthcoming)
Heusch G (2016) The coronary circulation as a target of cardioprotection. Circ Res 118:1643–1658. https://doi.org/10.1161/CIRCRESAHA.116.308640
doi: 10.1161/CIRCRESAHA.116.308640
pubmed: 27174955
Heusch G (2015) Molecular basis of cardioprotection: signal transduction in ischemic pre-, post-, and remote conditioning. Circ Res 116:674–699. https://doi.org/10.1161/CIRCRESAHA.116.305348
doi: 10.1161/CIRCRESAHA.116.305348
pubmed: 25677517
Heusch G (2020) Myocardial ischaemia-reperfusion injury and cardioprotection in perspective. Nat Rev Cardiol 17:773–789. https://doi.org/10.1038/s41569-020-0403-y
doi: 10.1038/s41569-020-0403-y
pubmed: 32620851
Heusch G, Botker HE, Przyklenk K, Redington A, Yellon D (2015) Remote ischemic conditioning. J Am Coll Cardiol 65:177–195. https://doi.org/10.1016/j.jacc.2014.10.031
doi: 10.1016/j.jacc.2014.10.031
pubmed: 25593060
pmcid: 4297315
Johnsen J, Pryds K, Salman R, Lofgren B, Kristiansen SB, Botker HE (2016) The remote ischemic preconditioning algorithm: effect of number of cycles, cycle duration and effector organ mass on efficacy of protection. Basic Res Cardiol 111:10. https://doi.org/10.1007/s00395-016-0529-6
doi: 10.1007/s00395-016-0529-6
pubmed: 26768477
Khan JN, Greenwood JP, Nazir SA, Lai FY, Dalby M, Curzen N, Hetherington S, Kelly DJ, Blackman D, Peebles C, Wong J, Flather M, Swanton H, Gershlick AH, McCann GP (2016) Infarct size following treatment with second- versus third-generation P2Y12 antagonists in patients with multivessel coronary disease at ST-segment elevation myocardial infarction in the CvLPRIT Study. J Am Heart Assoc 5(6):e003403. https://doi.org/10.1161/JAHA.116.003403
doi: 10.1161/JAHA.116.003403
pubmed: 27247336
pmcid: 4937278
Kim EK, Park TK, Yang JH, Song YB, Choi JH, Choi SH, Chun WJ, Choe YH, Gwon HC, Hahn JY (2017) Ticagrelor versus clopidogrel on myocardial infarct size in patients undergoing primary percutaneous coronary intervention. J Am Coll Cardiol 69:2098–2099. https://doi.org/10.1016/j.jacc.2017.02.034
doi: 10.1016/j.jacc.2017.02.034
pubmed: 28427585
Kleinbongard P, Botker HE, Ovize M, Hausenloy DJ, Heusch G (2019) Co-morbidities and co-medications as confounders of cardioprotection-Does it matter in the clinical setting? Br J Pharmacol. https://doi.org/10.1111/bph.14839
doi: 10.1111/bph.14839
Kleinbongard P, Skyschally A, Heusch G (2017) Cardioprotection by remote ischemic conditioning and its signal transduction. Pflug Arch 469:159–181. https://doi.org/10.1007/s00424-016-1922-6
doi: 10.1007/s00424-016-1922-6
Lieder HR, Irmert A, Kamler M, Heusch G, Kleinbongard P (2019) Sex is no determinant of cardioprotection by ischemic preconditioning in rats, but ischemic/reperfused tissue mass is for remote ischemic preconditioning. Physiol Rep 7:e14146. https://doi.org/10.14814/phy2.14146
doi: 10.14814/phy2.14146
pubmed: 31210033
pmcid: 6579942
Mehta SR, Tanguay JF, Eikelboom JW, Jolly SS, Joyner CD, Granger CB, Faxon DP, Rupprecht HJ, Budaj A, Avezum A, Widimsky P, Steg PG, Bassand JP, Montalescot G, Macaya C, Di Pasquale G, Niemela K, Ajani AE, White HD, Chrolavicius S, Gao P, Fox KA, Yusuf S, investigators C-Ot (2010) Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. Lancet 376:1233–1243. https://doi.org/10.1016/S0140-6736(10)61088-4
doi: 10.1016/S0140-6736(10)61088-4
pubmed: 20817281
Mehta SR, Yusuf S, Peters RJ, Bertrand ME, Lewis BS, Natarajan MK, Malmberg K, Rupprecht H, Zhao F, Chrolavicius S, Copland I, Fox KA, Clopidogrel in Unstable angina to prevent Recurrent Events trial I (2001) Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 358:527–533. https://doi.org/10.1016/s0140-6736(01)05701-4
doi: 10.1016/s0140-6736(01)05701-4
pubmed: 11520521
Meybohm P, Bein B, Brosteanu O, Cremer J, Gruenewald M, Stoppe C, Coburn M, Schaelte G, Boning A, Niemann B, Roesner J, Kletzin F, Strouhal U, Reyher C, Laufenberg-Feldmann R, Ferner M, Brandes IF, Bauer M, Stehr SN, Kortgen A, Wittmann M, Baumgarten G, Meyer-Treschan T, Kienbaum P, Heringlake M, Schon J, Sander M, Treskatsch S, Smul T, Wolwender E, Schilling T, Fuernau G, Hasenclever D, Zacharowski K, Collaborators RIS (2015) A multicenter trial of remote ischemic preconditioning for heart surgery. N Engl J Med 373:1397–1407. https://doi.org/10.1056/NEJMoa1413579
doi: 10.1056/NEJMoa1413579
pubmed: 26436208
Mohammad HMF, Makary S, Atef H, El-Sherbiny M, Atteia HH, Ibrahim GA, Mohamed AS, Zaitone SA (2020) Clopidogrel or prasugrel reduces mortality and lessens cardiovascular damage from acute myocardial infarction in hypercholesterolemic male rats. Life Sci 247:117429. https://doi.org/10.1016/j.lfs.2020.117429
doi: 10.1016/j.lfs.2020.117429
pubmed: 32061670
Montalescot G, van 't Hof AW, Lapostolle F, Silvain J, Lassen JF, Bolognese L, Cantor WJ, Cequier A, Chettibi M, Goodman SG, Hammett CJ, Huber K, Janzon M, Merkely B, Storey RF, Zeymer U, Stibbe O, Ecollan P, Heutz WM, Swahn E, Collet JP, Willems FF, Baradat C, Licour M, Tsatsaris A, Vicaut E, Hamm CW, Investigators A (2014) Prehospital ticagrelor in ST-segment elevation myocardial infarction. N Engl J Med 371:1016–1027. https://doi.org/10.1056/NEJMoa1407024
Mustafa SJ, Morrison RR, Teng B, Pelleg A (2009) Adenosine receptors and the heart: role in regulation of coronary blood flow and cardiac electrophysiology. Handb Exp Pharmacol. https://doi.org/10.1007/978-3-540-89615-9_6
doi: 10.1007/978-3-540-89615-9_6
pubmed: 19739338
pmcid: 2913612
Ozyuncu N, Goksuluk H, Tan TS, Esenboga K, Atmaca Y, Erol C (2020) Does the level of myocardial injury differ in primary angioplasty patients loaded first with clopidogrel and the ones with ticagrelor? Anatol J Cardiol 24:107–112. https://doi.org/10.14744/AnatolJCardiol.2020.22903
doi: 10.14744/AnatolJCardiol.2020.22903
pubmed: 32749245
pmcid: 7460681
Penna C, Aragno M, Cento AS, Femmino S, Russo I, Bello FD, Chiazza F, Collotta D, Alves GF, Bertinaria M, Zicola E, Mercurio V, Medana C, Collino M, Pagliaro P (2020) Ticagrelor conditioning effects are not additive to cardioprotection induced by direct NLRP3 inflammasome inhibition: role of RISK, NLRP3, and redox cascades. Oxid Med Cell Longev 2020:9219825. https://doi.org/10.1155/2020/9219825
doi: 10.1155/2020/9219825
pubmed: 32832010
pmcid: 7424511
Ramakers BP, Riksen NP, Stal TH, Heemskerk S, van den Broek P, Peters WH, van der Hoeven JG, Smits P, Pickkers P (2011) Dipyridamole augments the antiinflammatory response during human endotoxemia. Crit Care 15:R289. https://doi.org/10.1186/cc10576
doi: 10.1186/cc10576
pubmed: 22129171
pmcid: 3388652
Roe MT, Armstrong PW, Fox KA, White HD, Prabhakaran D, Goodman SG, Cornel JH, Bhatt DL, Clemmensen P, Martinez F, Ardissino D, Nicolau JC, Boden WE, Gurbel PA, Ruzyllo W, Dalby AJ, McGuire DK, Leiva-Pons JL, Parkhomenko A, Gottlieb S, Topacio GO, Hamm C, Pavlides G, Goudev AR, Oto A, Tseng CD, Merkely B, Gasparovic V, Corbalan R, Cinteza M, McLendon RC, Winters KJ, Brown EB, Lokhnygina Y, Aylward PE, Huber K, Hochman JS, Ohman EM, Investigators TA (2012) Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. N Engl J Med 367:1297–1309. https://doi.org/10.1056/NEJMoa1205512
doi: 10.1056/NEJMoa1205512
pubmed: 22920930
Roubille F, Lairez O, Mewton N, Rioufol G, Ranc S, Sanchez I, Cung TT, Elbaz M, Piot C, Ovize M (2012) Cardioprotection by clopidogrel in acute ST-elevated myocardial infarction patients: a retrospective analysis. Basic Res Cardiol 107:275. https://doi.org/10.1007/s00395-012-0275-3
doi: 10.1007/s00395-012-0275-3
pubmed: 22718009
Sabbah M, Nepper-Christensen L, Kober L, Hofsten DE, Ahtarovski KA, Goransson C, Kyhl K, Ghotbi AA, Schoos MM, Sadjadieh G, Kelbaek H, Lonborg J, Engstrom T (2020) Infarct size following loading with Ticagrelor/Prasugrel versus Clopidogrel in ST-segment elevation myocardial infarction. Int J Cardiol 314:7–12. https://doi.org/10.1016/j.ijcard.2020.05.011
doi: 10.1016/j.ijcard.2020.05.011
pubmed: 32389767
Schupke S, Neumann FJ, Menichelli M, Mayer K, Bernlochner I, Wohrle J, Richardt G, Liebetrau C, Witzenbichler B, Antoniucci D, Akin I, Bott-Flugel L, Fischer M, Landmesser U, Katus HA, Sibbing D, Seyfarth M, Janisch M, Boncompagni D, Hilz R, Rottbauer W, Okrojek R, Mollmann H, Hochholzer W, Migliorini A, Cassese S, Mollo P, Xhepa E, Kufner S, Strehle A, Leggewie S, Allali A, Ndrepepa G, Schuhlen H, Angiolillo DJ, Hamm CW, Hapfelmeier A, Tolg R, Trenk D, Schunkert H, Laugwitz KL, Kastrati A, Investigators I-RT (2019) Ticagrelor or prasugrel in patients with acute coronary syndromes. N Engl J Med 381:1524–1534. https://doi.org/10.1056/NEJMoa1908973
doi: 10.1056/NEJMoa1908973
pubmed: 31475799
Skyschally A, van Caster P, Iliodromitis EK, Schulz R, Kremastinos DT, Heusch G (2009) Ischemic postconditioning: experimental models and protocol algorithms. Basic Res Cardiol 104:469–483. https://doi.org/10.1007/s00395-009-0040-4
doi: 10.1007/s00395-009-0040-4
pubmed: 19543787
Spreeuwenberg MD, Bartak A, Croon MA, Hagenaars JA, Busschbach JJ, Andrea H, Twisk J, Stijnen T (2010) The multiple propensity score as control for bias in the comparison of more than two treatment arms: an introduction from a case study in mental health. Med Care 48:166–174. https://doi.org/10.1097/MLR.0b013e3181c1328f
doi: 10.1097/MLR.0b013e3181c1328f
pubmed: 20068488
Sugidachi A, Ogawa T, Kurihara A, Hagihara K, Jakubowski JA, Hashimoto M, Niitsu Y, Asai F (2007) The greater in vivo antiplatelet effects of prasugrel as compared to clopidogrel reflect more efficient generation of its active metabolite with similar antiplatelet activity to that of clopidogrel’s active metabolite. J Thromb Haemost 5:1545–1551. https://doi.org/10.1111/j.1538-7836.2007.02598.x
doi: 10.1111/j.1538-7836.2007.02598.x
pubmed: 17456192
Sugidachi A, Ohno K, Ogawa T, Jakubowski J, Hashimoto M, Tomizawa A (2013) A comparison of the pharmacological profiles of prasugrel and ticagrelor assessed by platelet aggregation, thrombus formation and haemostasis in rats. Br J Pharmacol 169:82–89. https://doi.org/10.1111/bph.12108
doi: 10.1111/bph.12108
pubmed: 23347039
pmcid: 3632240
Sugidachi A, Yamaguchi S, Jakubowski JA, Ohno K, Tomizawa A, Hashimoto M, Niitsu Y (2011) Selective blockade of P2Y12 receptors by prasugrel inhibits myocardial infarction induced by thrombotic coronary artery occlusion in rats. J Cardiovasc Pharmacol 58:329–334. https://doi.org/10.1097/FJC.0b013e3182244a6f
doi: 10.1097/FJC.0b013e3182244a6f
pubmed: 21697729
Terkelsen CJ, Sorensen JT, Maeng M, Jensen LO, Tilsted HH, Trautner S, Vach W, Johnsen SP, Thuesen L, Lassen JF (2010) System delay and mortality among patients with STEMI treated with primary percutaneous coronary intervention. JAMA 304:763–771. https://doi.org/10.1001/jama.2010.1139
doi: 10.1001/jama.2010.1139
pubmed: 20716739
Ubaid S, Ford TJ, Berry C, Murray HM, Wrigley B, Khan N, Thomas MR, Armesilla AL, Townend JN, Khogali SS, Munir S, Martins J, Hothi SS, McAlindon EJ, Cotton JM (2019) Cangrelor versus ticagrelor in patients treated with primary percutaneous coronary intervention: impact on platelet activity, myocardial microvascular function and infarct size: a randomized controlled trial. Thromb Haemost 119:1171–1181. https://doi.org/10.1055/s-0039-1688789
doi: 10.1055/s-0039-1688789
pubmed: 31129911
van den Berg TN, El Messaoudi S, Rongen GA, van den Broek PH, Bilos A, Donders AR, Gomes ME, Riksen NP (2015) Ticagrelor does not inhibit adenosine transport at relevant concentrations: a randomized cross-over study in healthy subjects in vivo. PLoS ONE 10:e0137560. https://doi.org/10.1371/journal.pone.0137560
doi: 10.1371/journal.pone.0137560
pubmed: 26509673
pmcid: 4624811
van der Hoeven NW, Janssens GN, Everaars H, Nap A, Lemkes JS, de Waard GA, van de Ven PM, van Rossum AC, Escaned J, Mejia-Renteria H, Ten Cate TJF, Piek JJ, von Birgelen C, Valgimigli M, Diletti R, Riksen NP, Van Mieghem NM, Nijveldt R, van Leeuwen MAH, van Royen N (2020) Platelet inhibition, endothelial function, and clinical outcome in patients presenting with st-segment-elevation myocardial infarction randomized to ticagrelor versus prasugrel maintenance therapy: long-term follow-up of the REDUCE-MVI trial. J Am Heart Assoc 9:e014411. https://doi.org/10.1161/JAHA.119.014411
doi: 10.1161/JAHA.119.014411
pubmed: 32122216
pmcid: 7335553
van Giezen JJ, Sidaway J, Glaves P, Kirk I, Bjorkman JA (2012) Ticagrelor inhibits adenosine uptake in vitro and enhances adenosine-mediated hyperemia responses in a canine model. J Cardiovasc Pharmacol Ther 17:164–172. https://doi.org/10.1177/1074248411410883
doi: 10.1177/1074248411410883
pubmed: 21697355
van Leeuwen MAH, van der Hoeven NW, Janssens GN, Everaars H, Nap A, Lemkes JS, de Waard GA, van de Ven PM, van Rossum AC, Ten Cate TJF, Piek JJ, von Birgelen C, Escaned J, Valgimigli M, Diletti R, Riksen NP, van Mieghem NM, Nijveldt R, van Royen N (2019) Evaluation of microvascular injury in revascularized patients with ST-segment-elevation myocardial infarction treated with ticagrelor versus prasugrel. Circulation 139:636–646. https://doi.org/10.1161/CIRCULATIONAHA.118.035931
doi: 10.1161/CIRCULATIONAHA.118.035931
pubmed: 30586720
Vannini L, Muro A, Sanchis J, Ortiz-Perez JT, Flores Umanzor E, Lopez-Lereu MP, Badimon L, Sabate M, Brugaletta S (2016) Can new generation P2Y12 inhibitors play a role in microvascular obstruction in STEMI? Int J Cardiol 223:226–227. https://doi.org/10.1016/j.ijcard.2016.08.182
doi: 10.1016/j.ijcard.2016.08.182
pubmed: 27541661
Vilahur G, Arzanauskaite M, Sutelman P (2020) Ticagrelor in post-STEMI adverse ventricular remodeling: there is more than meets the platelet. JACC Cardiovasc Interv 13:2235–2237. https://doi.org/10.1016/j.jcin.2020.09.006
doi: 10.1016/j.jcin.2020.09.006
pubmed: 33032711
Vilahur G, Gutierrez M, Casani L, Lambert C, Mendieta G, Ben-Aicha S, Capdevila A, Pons-Llado G, Carreras F, Carlsson L, Hidalgo A, Badimon L (2018) P2Y12 antagonists and cardiac repair post-myocardial infarction: global and regional heart function analysis and molecular assessments in pigs. Cardiovasc Res 114:1860–1870. https://doi.org/10.1093/cvr/cvy201
doi: 10.1093/cvr/cvy201
pubmed: 30124783
Vilahur G, Gutierrez M, Casani L, Varela L, Capdevila A, Pons-Llado G, Carreras F, Carlsson L, Hidalgo A, Badimon L (2016) Protective effects of ticagrelor on myocardial injury after infarction. Circulation 134:1708–1719. https://doi.org/10.1161/CIRCULATIONAHA.116.024014
doi: 10.1161/CIRCULATIONAHA.116.024014
pubmed: 27789556
Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, Mahaffey KW, Scirica BM, Skene A, Steg PG, Storey RF, Harrington RA, Investigators P, Freij A, Thorsen M (2009) Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 361:1045–1057. https://doi.org/10.1056/NEJMoa0904327
doi: 10.1056/NEJMoa0904327
pubmed: 19717846
Weisshaar S, Litschauer B, Eipeldauer M, Hobl EL, Wolzt M (2017) Ticagrelor mitigates ischaemia-reperfusion induced vascular endothelial dysfunction in healthy young males—a randomized, single-blinded study. Br J Clin Pharmacol 83:2651–2660. https://doi.org/10.1111/bcp.13378
doi: 10.1111/bcp.13378
pubmed: 28715608
pmcid: 5698593
Wittfeldt A, Emanuelsson H, Brandrup-Wognsen G, van Giezen JJ, Jonasson J, Nylander S, Gan LM (2013) Ticagrelor enhances adenosine-induced coronary vasodilatory responses in humans. J Am Coll Cardiol 61:723–727. https://doi.org/10.1016/j.jacc.2012.11.032
doi: 10.1016/j.jacc.2012.11.032
pubmed: 23312702
Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, Neumann FJ, Ardissino D, De Servi S, Murphy SA, Riesmeyer J, Weerakkody G, Gibson CM, Antman EM, Investigators T-T (2007) Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 357:2001–2015. https://doi.org/10.1056/NEJMoa0706482
doi: 10.1056/NEJMoa0706482
pubmed: 17982182
Wu Q, Gui P, Wu J, Ding D, Purusram G, Dong N, Yao S (2011) Effect of limb ischemic preconditioning on myocardial injury in patients undergoing mitral valve replacement surgery. A randomized controlled trial. Circ J 75:1885–1889. https://doi.org/10.1253/circj.cj-10-1130
doi: 10.1253/circj.cj-10-1130
pubmed: 21697609
Yang XM, Cui L, Alhammouri A, Downey JM, Cohen MV (2013) Triple therapy greatly increases myocardial salvage during ischemia/reperfusion in the in situ rat heart. Cardiovasc Drugs Ther 27:403–412. https://doi.org/10.1007/s10557-013-6474-9
doi: 10.1007/s10557-013-6474-9
pubmed: 23832692
Yang XM, Gadde S, Audia JP, Alvarez DF, Downey JM, Cohen MV (2019) Ticagrelor does not protect isolated rat hearts, thus clouding its proposed cardioprotective role through ENT 1 in heart tissue. J Cardiovasc Pharmacol Ther 24:371–376. https://doi.org/10.1177/1074248419829169
doi: 10.1177/1074248419829169
pubmed: 30744423
pmcid: 7400974
Yang XM, Liu Y, Cui L, Yang X, Liu Y, Tandon N, Kambayashi J, Downey JM, Cohen MV (2013) Platelet P2Y(1)(2) blockers confer direct postconditioning-like protection in reperfused rabbit hearts. J Cardiovasc Pharmacol Ther 18:251–262. https://doi.org/10.1177/1074248412467692
doi: 10.1177/1074248412467692
pubmed: 23233653
Yang XM, Liu Y, Cui L, Yang X, Liu Y, Tandon N, Kambayashi J, Downey JM, Cohen MV (2013) Two classes of anti-platelet drugs reduce anatomical infarct size in monkey hearts. Cardiovasc Drugs Ther 27:109–115. https://doi.org/10.1007/s10557-012-6436-7
doi: 10.1007/s10557-012-6436-7
pubmed: 23318690
Ye Y, Birnbaum GD, Perez-Polo JR, Nanhwan MK, Nylander S, Birnbaum Y (2015) Ticagrelor protects the heart against reperfusion injury and improves remodeling after myocardial infarction. Arterioscler Thromb Vasc Biol 35:1805–1814. https://doi.org/10.1161/ATVBAHA.115.305655
doi: 10.1161/ATVBAHA.115.305655
pubmed: 26044583
Yellon DM, Hausenloy DJ (2007) Myocardial reperfusion injury. N Engl J Med 357:1121–1135. https://doi.org/10.1056/NEJMra071667
doi: 10.1056/NEJMra071667
pubmed: 17855673
Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK, Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial I (2001) Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 345:494–502. https://doi.org/10.1056/NEJMoa010746
doi: 10.1056/NEJMoa010746
pubmed: 11519503
Ziegler M, Wang X, Peter K (2019) Platelets in cardiac ischaemia/reperfusion injury: a promising therapeutic target. Cardiovasc Res 115:1178–1188. https://doi.org/10.1093/cvr/cvz070
doi: 10.1093/cvr/cvz070
pubmed: 30906948
pmcid: 6529900